Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Tissue Eng Part B Rev. 2009 Jun;15(2):195-200. doi: 10.1089/ten.TEB.2008.0515.
There has long been a described relationship between mesenchymal stem cells (MSCs) and blood vessels in aspects of bone and other skeletal tissues with regard to their embryonic formation and their adult repair and regeneration dynamics. The use of exogenously added MSCs to supplement the naturally available progenitor cell stock has been a standard practice in several orthopedic surgeries by adding bone marrow to the repair constructs. This, coupled with the well-established need for vasculature to orient and drive bone formation, firmly established the functional relationship between MSCs, osteoprogenitors, and blood vessels. It is now apparent that MSCs are pericytes (cells that surround blood vessels) throughout the body. In addition, MSCs can function to secrete bioactive factors that are immunomodulatory, thus allowing allogeneic MSCs to be infused into patients requiring clinically relevant treatments. Such infused MSCs trophically establish microenvironments that support the regeneration of the injured tissue. These new functions usher in a new era of cell-based therapies.
长期以来,间充质干细胞 (MSCs) 与血管之间存在一种描述性关系,无论是在胚胎形成方面,还是在骨骼和其他骨骼组织的成人修复和再生动态方面。在几种矫形外科手术中,通过将骨髓添加到修复结构中,将外源性添加的 MSCs 用于补充天然可用的祖细胞库存已经成为一种标准做法。这一点,再加上血管对定向和驱动骨形成的既定需求,牢固确立了 MSCs、成骨前体细胞和血管之间的功能关系。现在很明显,MSCs 是全身的周细胞(包围血管的细胞)。此外,MSCs 可以分泌具有免疫调节作用的生物活性因子,从而允许同种异体 MSCs 输注到需要临床相关治疗的患者中。这种输注的 MSCs 营养性地建立了微环境,支持受伤组织的再生。这些新功能开创了细胞治疗的新时代。